The FDA has approved the weight-loss drug Zepbound to treat obstructive sleep apnea. Medical correspondents report that the drug could effectively cure symptoms in 40% of patients. The hosts discuss the potential for Medicare and Medicaid to cover the high cost of these injectable medications, estimated at $30 billion over ten years.







